GW Pharmaceuticals gets more clinical backing

GW Pharmaceuticals, the British biotech firm, has seen clinical data released by partner Almirall that gives further backing for the efficacy of GW's cannabis-based drug, Sativex.

GW Pharmaceuticals, the British biotech firm, has seen clinical data released by partner Almirall that gives further backing for the efficacy of GW's cannabis-based drug, Sativex.

The results of a study in Germany with 300 patients was released at a major conference in France. The study found that Sativex reduced the symptoms of moderate to severe spasticity due to multiple sclerosis.

The data confirmed that after three months, 41% of patients treated with Sativex, who were resistant to other therapies, showed a clinically relevant response.

The medicine has been proven to be a cost-effective treatment in Germany where Almirall has already made it available, as well as Spain and Denmark.

Next year GW Pharma is expecting the results of Phase III study into Sativex's efficacy as a treatment for cancer pain.

GW's cancer pain clinical programme is being wholly funded by Otsuka Pharmaceutical, which has licensed the US commercialisation rights to this product.

Sativex is licensed to Otsuka in the US, Almirall in Europe (excluding the United Kingdom) and Mexico, Bayer HealthCare in the UK and Canada, Novartis Pharma in Australasia, Asia (excluding Japan and China), Middle East (excluding Israel) and Africa, and Neopharm Group in Israel.

CM

Recommended

The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves takes a look at the companies with the highest dividend yields in the UK’s blue-chip index
6 Feb 2023
The outlook for Shell shares is mixed, despite bumper profits
Energy stocks

The outlook for Shell shares is mixed, despite bumper profits

With profits surging, it looks as if Shell is on a roll, but the company’s growth from here is hard to see as Rupert Hargreaves explains.
6 Feb 2023
The top funds to invest in
Funds

The top funds to invest in

As market volatility and recessionary fears continue, here are the most popular funds, stocks and trusts investors are putting their money into accord…
2 Feb 2023
The top ten dividend stocks in the FTSE 250
Share tips

The top ten dividend stocks in the FTSE 250

The average FTSE 250 dividend yield is around 4%, but many stocks yield much more. Rupert Hargreaves picks the best FTSE 250 stocks for income investo…
17 Jan 2023

Most Popular

Best savings accounts – February 2023
Savings

Best savings accounts – February 2023

Interest rates on cash savings are making a comeback. We look at the best savings accounts on the market now
6 Feb 2023
The best one-year fixed savings accounts - February 2023
Savings

The best one-year fixed savings accounts - February 2023

Earn almost 5% on one-year fixed savings accounts.
6 Feb 2023
Share tips of the week – 3 February 2023
Investments

Share tips of the week – 3 February 2023

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages
3 Feb 2023